Human Papillomaviruses1

The Vaccine Book

Volumn , Issue , 2003, Pages 311-322

  Gissmann, Lutz ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 70350086302     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012107258-2/50024-X     Document Type: Chapter

References (38)

1. de Villiers E.M. Taxonomic Classification of Papillomaviruses. Papillomavirus Rep. 2001, 12:57-63.
2. Bosch F.X., Manos M.M., Munoz N., Sherman M., Jansen A.M., Peto J., Schiffman M.H., Moreno V., Kurman R., Shah K.V. Prevalence of human papillomavirus in cervical cancer: A worldwide perspective. International Biological Study on Cervical Cancer (IBSCC) Study Group [see comments]. J. Natl. Cancer Inst. 1995, 87:796-802.
3. IARC Human Papillomaviruses 1995, IARC, Lyon, France.
4. zur Hausen H. Papillomaviruses in human cancers. Proc. Assoc. Am. Physicians 1999, 111:581-587.
5. Kashima H., Mounts P. Tumors of the Head and Neck, Larynx, Lung and Esophagus and Their Possible Relation to HPV. Papillomaviruses and Human Disease 1987, 138-157. Springer Verlag, Berlin. K. Syrjänen, L. Gissmann, L. Koss (Eds.).
6. Sonnex C. The clinical features of genital and perigenital human papillomavirus infection. Genital Warts: Human Papillomavirus Infection 1995, 82-104. Edward Arnold, London. A. Mindel (Ed.).
7. Gross G., von Krogh G., Barrasso R. Genitoanal Lesions. Human Papillomavirus Infections in Dermatovenerology 1997, 389-416. CRC Press, Boca Raton, FL. G. Gross, G. von Krogh (Eds.).
8. Edwards L. Imiquimod in clinical practice. J. Am. Acad. Dermatol. 2000, 43:S12-S17.
9. Franco E.L. Epidemiology of anogenital warts and cancer. Obstet Gynecol. Clin. North Am. 1996, 23:597-623.
10. Naryshkin S. The false-negative fraction for Papanicolaou smears: How often are "abnormal" smears not detected by a "standard" screening cytologist?. Arch. Pathol. Lab. Med. 1997, 121:270-272.
11. National Cancer Institute Cancer Facts 2001, http://cis.nci.nih.gov/fact/5_16.htm.
12. Parkin D.M., Pisani P., Ferlay J. Estimates of the worldwide incidence of 25 major cancers in 1990. Int. J. Cancer 1999, 80:827-841.
13. Dillner J. The serological response to papillomaviruses. Semin. Cancer Biol. 1999, 9:423-430.
14. Konya J., Dillner J. Immunity to oncogenic human papillomaviruses. Adv. Cancer Res. 2001, 82:205-238.
15. Stern P.L., Brown M., Stacey S.N., Kitchener H.C., Hampson I., Abdel-Hady E.S., Moore J.V. Natural HPV immunity and vaccination strategies. J. Clin. Virol. 2000, 19:57-66.
16. Breitburd F., Coursaget P. Human papillomavirus vaccines. Semin. Cancer Biol. 1999, 9:431-444.
17. Schiller J.T., Roden R.B.S. Papillomavirus-like particles. Papillomavirus Rep. 1995, 6:121-128.
18. Gissmann L., Osen W., Müller M., Jochmus I. Therapeutic vaccines for human papillomaviruses. Intervirology 2001, 44:167-175.
19. Da Silva D.M., Eiben G.L., Fausch S.C., Wakabayashi M.T., Rudolf M.P., Velders M.P., Kast W.M. Cervical cancer vaccines: Emerging concepts and developments. J. Cell. Physiol. 2001, 186:169-182.
20. Hoover D.R., Carfioli B., Moench E.A. Attitudes of adolescent/young adult women toward human papillomavirus vaccination and clinical trials. Health Care Women Int. 2000, 21:375-391.
21. Dillner J., Meijer C.J., von Krogh G., Horenblas S. Epidemiology of human papillomavirus infection. Scand. J. Urol. Nephrol. 2000, 205:194-200.
22. Herrero, R. (2000). Personal communication.
23. van der Burg S.H., Kwappenberg K.M., O'Neill T., Brandt R.M., Melief C.J., Hickling J.K., Offringa R. Pre-clinical safety and efficacy of TA-CIN, a recombinant HPV16 L2E6E7 fusion protein vaccine, in homologous and heterologous prime-boost regimens. Vaccine 2001, 19:3652-3660.
24. Borysiewicz L.K., Fiander A., Nimako M., Man S., Wilkinson G.W., Westmoreland D., Evans A.S., Adams M., Stacey S.N., Boursnell M.E., Rutherford E., Hickling J.K., Inglis S.C. A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. Lancet 1996, 347:1523-1527.
25. Steller M.A., Gurski K.J., Murakami M., Daniel R.M., Shah K.V., Celis E., Sette A., Trimble E.L., Park R.C., Marincola F.M. Cell-mediated immunological responses in cervical and vaginal cancer patients immunized with a lipidated epitope of human papillomavirus type 16 E7. Clin. Cancer Res. 1998, 4:2103-2109.
26. Lacey C.J., Thompson H.S., Monteiro E.F., O'Neill T., Davies M.L., Holding F.P., Fallon R.E., Roberts J.S. Phase IIa safety and immunogenicity of a therapeutic vaccine, TA-GW, in persons with genital warst. J. Infect. Dis. 1999, 179:612-618.
27. Thompson H.S., Davies M.L., Holding F.P., Fallon R.E., Mann A.E., O'Neill T., Roberts J.S. Phase I safety and antigenicity of TA-GW: a recombinant HPV6 L2E7 vaccine for the treatment of genital warts. Vaccine 1999, 17:40-49.
28. van Driel W.J., Ressing M.E., Kenter G.G., Brandt R.M., Krul E.J., van Rossum A.B., Schuuring E., Offringa R., Bauknecht T., Tamm-Hermelink A., van Dam P.A., Fleuren G.J., Kast W.M., Melief C.J., Trimbos J.B. Vaccination with HPV16 peptides of patients with advanced cervical carcinoma: Clinical evaluation of a phase I-II trial. Eur. J. Cancer 1999, 35:946-952.
29. Muderspach L., Wilczynski S., Roman L., Bade L., Felix J., Small L.A., Kast W.M., Fascio G., Marty V., Weber J. A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive. Clin. Cancer Res. 2000, 6:3406-3416.
30. Zhang L.F., Zhou J., Chen S., Cai L.L., Bao Q.Y., Zheng F.Y., Lu J.Q., Padmanabha J., Hengst K., Malcolm K., Frazer I.H. HPV6b virus like particles are potent immunogens without adjuvant in man. Vaccine 2000, 18:1051-1058.
31. Evans T.G., Bonnez W., Rose R.C., Koenig S., Demeter L., Suzich J.A., O'Brien D., Campbell M., White W.I., Balsley J., Reichman R.C. A Phase 1 study of a recombinant viruslike particle vaccine against human papillomavirus type 11 in healthy adult volunteers. J. Infect. Dis. 2001, 183:1485-1493.
32. Harro C.D., Pang Y.Y., Roden R.B., Hildesheim A., Wang Z., Reynolds M.J., Mast T.C., Robinson R., Murphy B.R., Karron R.A., Dillner J., Schiller J.T., Lowy D.R. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J. Natl. Cancer Inst. 2001, 93:284-292.
33. Adams M., Borysiewicz L., Fiander A., Man S., Jasani B., Navabi H., Lipetz C., Evans A.S., Mason M. Clinical studies of human papilloma vaccines in pre-invasive and invasive cancer. Vaccine 2001, 19:2549-2556.
34. Tindle R. Vaccines for Human Papillomavirus Infection and Anogenital Disease 1999, RG Landes Company, Austin, TX.
35. 18th International Papillomavirus Conference 2000, http://www.ipvsoc.org.
36. 19th International Papillomavirus Conference 2001, http://www.ipvsoc.org.
37. Herrero R., Hildesheim A., Bratti C., Sherman M.E., Hutchinson M., Morales J., Balmaceda I., Greenberg M.D., Alfaro M., Burk R.D., Wacholder S., Plummer M., Schiffman M. Population-based study of human papillomavirus infection and cervical neoplasia in rural Costa Rica. J Natl. Cancer Inst. 2000, 92:464-474.
38. Schiller J.T., Hildesheim A. Developing HPV virus-like particle vaccines to prevent cervical cancer: A progress report. J. Clin. Virol. 2000, 19:67-74.